David Redfern - GSK Plc Chief Strategy Officer
| GLAXF Stock | USD 16.87 0.17 1.00% |
Executive
Mr. David Redfern is Chief Strategy Officer of GlaxoSmithKline PLC. David joined the CET as Chief Strategy Officer in 2008 and is responsible for corporate development and strategic planning. Previously, he was Senior Vice President, Northern Europe with responsibility for GSKs pharmaceutical businesses in that region and, prior to that, he was Senior Vice President for Central and Eastern Europe. He joined GSK in 1994. David was appointed Chairman of the Board of ViiV Healthcare Limited in 2011 and a NonExecutive Director of the Aspen Pharmacare Holdings Limited Board in 2015. He has a BS degree from Bristol University and is a Chartered Accountant. since 2008.
| Age | 57 |
| Tenure | 16 years |
| Phone | 44 20 8047 5000 |
| Web | https://www.gsk.com |
GSK Plc Management Efficiency
The company has return on total asset (ROA) of 0.0659 % which means that it generated a profit of $0.0659 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3131 %, meaning that it generated $0.3131 on every $100 dollars invested by stockholders. GSK Plc's management efficiency ratios could be used to measure how well GSK Plc manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Cristina Wilbur | Roche Holding Ltd | 56 | |
| Rudolf Ertl | Gilead Sciences | 78 | |
| Heiko Schipper | Bayer AG | 54 | |
| Kave Niksefat | Amgen Inc | N/A | |
| Stefan Oelrich | Bayer AG | 55 | |
| Flavius MD | Gilead Sciences | N/A | |
| Johanna Mercier | Gilead Sciences | 54 | |
| Mikael MD | Pfizer Inc | 66 | |
| Robert Weltevreden | Novartis AG ADR | 52 | |
| Joseph Eiden | Bristol Myers Squibb | 75 | |
| Madeleine Roach | Sanofi ADR | 40 | |
| Alan Hippe | Roche Holding Ltd | 56 | |
| Cristina Wilbur | Roche Holding AG | 56 | |
| Samit MD | Bristol Myers Squibb | 55 | |
| William Winters | Novartis AG ADR | 60 | |
| Ruth March | AstraZeneca PLC ADR | N/A | |
| Steffen Lang | Novartis AG | 56 | |
| Matthew Busch | Amgen Inc | 50 | |
| Shozo Matsuoka | Ono Pharmaceutical Co | 58 | |
| Alan Russell | Amgen Inc | N/A | |
| Francesca DeMartino | Pfizer Inc | N/A | |
Management Performance
| Return On Equity | 0.31 | |||
| Return On Asset | 0.0659 |
GSK plc Leadership Team
Elected by the shareholders, the GSK Plc's board of directors comprises two types of representatives: GSK Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GSK. The board's role is to monitor GSK Plc's management team and ensure that shareholders' interests are well served. GSK Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GSK Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Redfern, Chief Strategy Officer | ||
| Diana Conrad, Chief Officer | ||
| Emma Walmsley, President - Consumer Healthcare Worldwide | ||
| Sally Jackson, VP Office | ||
| Iain Mackay, CFO - Designate, Executive Director | ||
| James Ford, Senior Vice President General Counsel | ||
| Shobie Ramakrishnan, Chief Officer | ||
| Sarah EltonFarr, Head Relations | ||
| Julie Brown, Chief Officer | ||
| Tony Wood, Chief Officer |
GSK Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is GSK Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.31 | |||
| Return On Asset | 0.0659 | |||
| Profit Margin | 0.51 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 90.86 B | |||
| Shares Outstanding | 4.09 B | |||
| Shares Owned By Insiders | 0.60 % | |||
| Shares Owned By Institutions | 41.06 % | |||
| Price To Earning | 11.44 X | |||
| Price To Book | 6.49 X |
Currently Active Assets on Macroaxis
Other Information on Investing in GSK Pink Sheet
GSK Plc financial ratios help investors to determine whether GSK Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GSK with respect to the benefits of owning GSK Plc security.